The influence of experimental alcohol load and alcohol intoxication on S100B concentrations Brin T, Borucki K and Ambrosch A Shock 2011;36:356-60 S100B, a calcium-binding protein, is located primarily in astrocytes and Schwann cells. It is released into the circulation following traumatic brain injury (TBI) and a low concentration of SI00B has a good negative predictive value to not proceed to computed tomography (CT) scan. S100B measurement in patients presenting with suspected minor TBI could potentially reduce the number of CT scans performed by 30%. It may be particularly useful in alcohol-intoxicated patients where symptoms of brain injury and intoxication are similar. However, the effect of alcohol ingestion on serum S100B concentration is not established and previous studies have produced conflicting results.
S100B, a calcium-binding protein, is located primarily in astrocytes and Schwann cells. It is released into the circulation following traumatic brain injury (TBI) and a low concentration of SI00B has a good negative predictive value to not proceed to computed tomography (CT) scan. S100B measurement in patients presenting with suspected minor TBI could potentially reduce the number of CT scans performed by 30%. It may be particularly useful in alcohol-intoxicated patients where symptoms of brain injury and intoxication are similar. However, the effect of alcohol ingestion on serum S100B concentration is not established and previous studies have produced conflicting results.
The effect of increased blood alcohol concentration on serum S100B concentrations (Roche Elecsys) in two groups was investigated. Twelve healthy volunteers (group 1) were given an oral alcohol load (ethyl alcohol), followed by alcohol infusion until blood alcohol concentrations reached steady state (100 mg/dL). S100B was measured prealcohol infusion, and then hourly for five hours once steady state had been achieved. Group 2 comprised 61 nontraumatized, ethyl alcohol-intoxicated individuals (mean ethanol 251 + 87 mg/dL) presenting to accident and emergency due to their intoxication but with no biochemical evidence of chronic alcohol abuse. S100B was measured on admission and compared against concentrations in 60 anthropometrically matched sober volunteers. An S100B concentration ,0.105 mg/L was considered normal.
Alcohol infusion had no effect on S100B concentrations in group 1. However, mean serum S100B concentration in group 2 was raised (0.193 + 0.45 mg/L) relative to the control group (0.063 + 0.059 mg/L). Many (39%) intoxicated individuals, but no controls, had S100B concentrations .0.105 mg/L. No correlation was demonstrated between alcohol and S100B concentration.
Subjects were screened for extracranial sources of S100B before inclusion in the study; therefore, these results appear to show a genuine increase in S100B associated with alcohol consumption in some individuals. Differences between the intoxicated and infused groups could be explained by higher blood alcohol concentrations in most of the intoxicated individuals. In conclusion, alcohol concentrations above 100 mg/dL may result in an increase in S100B concentration.
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The pathogenesis of Graves' disease (GD) is not fully understood. However, aberrant inflammatory cytokine production following stimulation of thyroid-stimulating hormone (TSH) receptors by autoantibodies has been implicated. Osteopontin, a multifunctional extracellular matrix protein, has recently been identified as a biomarker for various autoimmune diseases. This study addressed the role of osteopontin in GD.
Osteopontin, interferon-a (IFN-a) and interferon-g (IFN-g) were measured by enzyme-linked immunosorbent assay in serum from GD patients (n ¼ 76) and healthy controls (n ¼ 65). mRNA expression of osteopontin and its receptors (integrins), cytokines and chemokines in peripheral blood mononuclear cells (PBMC) from GD patients and controls was assessed by quantitative reverse transcriptase-polymerase chain reaction. The effect of osteopontin on activating nuclear factor-kB (NF-kB) activation was determined by plasmid transfection of HeLa cells using a luciferase reporter assay.
Serum osteopontin concentrations correlated significantly with typical biochemical features of GD including thyroxine (FT 4 ) (r ¼ 0.43; P ¼ 0.004), triiodothyronine (FT 3 ) (r ¼ 0.36; P ¼ 0.02), TSH receptor antibody (r ¼ 0.54; P , 0.001) and TSH concentrations (r ¼ 20.56; P , 0.001). Furthermore, serum osteopontin concentrations and mRNA levels in PBMC from GD patients were significantly higher than healthy controls (P , 0.001). Serum IFN-a and IFN-g were significantly increased in GD patients (P , 0.001). There was a selective elevation in expression of osteopontin receptors av, b1, b3 and CD44, and the proinflammatory cytokines IL-1b and IL-8, and chemokines CCL2 and CCL3, in PBMC from GD patients (all P , 0.05). The expression of these NF-kB downstream target genes correlated significantly with osteopontin concentration. In vitro assays showed that serum from GD patients enhanced NF-kB activation, which was suppressed by osteopontin abrogation using a monoclonal antibody.
This clinical correlation between serum osteopontin concentration and GD suggests that osteopontin could serve as a novel biomarker for GD. The authors speculate that osteopontin may affect GD development via NF-kB activation and the subsequent change in inflammatory milieu. Therefore, osteopontin might be a potential therapeutic target in GD and other autoimmune diseases.
